Table 1.
Characteristic | Men (n=12 861) | Women (n=2967) | P Value |
---|---|---|---|
Age, y | 64.0 (58.0–71.0) | 66.0 (61.0–72.0) | <0.001 |
Current smoker | 2439 (19.0) | 419 (14.1) | <0.001 |
Diabetes mellitus | 4836 (37.6) | 1300 (43.8) | <0.001 |
Hypertension | 9011 (70.1) | 2307 (77.8) | <0.001 |
Chronic kidney disease | 3637 (28.3) | 1152 (38.8) | <0.001 |
Congestive heart failure | 2691 (20.9) | 691 (23.3) | 0.005 |
Prior MI | 7654 (59.5) | 1669 (56.3) | 0.001 |
Prior revascularization | 9756 (75.9) | 2107 (71.0) | <0.001 |
Any history of prior stroke | 790 (6.1) | 185 (6.2) | 0.85 |
Prior peripheral artery disease | 440 (3.4) | 111 (3.7) | 0.39 |
Multivessel CHD | 1913 (14.9) | 477 (16.1) | 0.10 |
Polyvascular disease | 1912 (14.9) | 460 (15.5) | 0.381 |
Body mass index, kg/m2 | 28.2 (25.6–31.5) | 28.6 (25.3–32.6) | <0.001 |
Region of enrollment | <0.001 | ||
Asia/Pacific | 2526 (19.6) | 563 (19.0) | |
Eastern Europe | 2757 (21.4) | 774 (26.1) | |
North America | 3330 (25.9) | 693 (23.4) | |
South America | 937 (7.3) | 262 (8.8) | |
Western Europe | 3311 (25.7) | 675 (22.8) | |
Baseline systolic blood pressure, mm Hg | 131 (120–142) | 130 (119–143) | 0.57 |
Baseline LpPLA2, μmol/min/L | 177.2 (148.8–208.6) | 150.4 (125.4–180.7) | <0.001 |
Baseline hs‐CRP, mg/L | 1.3 (0.6–2.9) | 1.6 (0.8–3.8) | 0.002 |
Baseline HDL cholesterol, mmol/L | 1.1 (1.0–1.3) | 1.3 (1.1–1.6) | <0.001 |
Baseline LDL cholesterol, mmol/L | 2.1 (1.6–2.6) | 2.2 (1.7–2.8) | <0.001 |
Baseline HbA1c,* % | 7.0 (6.3–8.0) | 7.2 (6.5–8.4) | <0.001 |
Baseline eGFR, mL/min/1.73 m2 | 78.0 (66.0–90.0) | 66.0 (60.0–78.0) | <0.001 |
Data provided as median (25th–75th percentiles) or n (%). CHD indicates coronary heart disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; hs‐CRP, high‐sensitivity C‐reactive protein; LDL, low‐density lipoprotein; LpPLA2, lipoprotein‐associated phospholipase A2; MI, myocardial infarction.*Among patients with diabetes mellitus.